Perspective Therapeutics, Inc.

Perspective Therapeutics announced updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for neuroendocrine tumors. The data, presented at ESMO 2026, showed encouraging safety and efficacy, including objective response rates of 33% and 50% in dose cohorts 2 and 3, respectively, and 72% progression-free survival at 18 months. The company is preparing for Phase 3 trial initiation in 2027.

Perspective Therapeutics reported a net loss of $26.8 million for the second quarter of 2026 and $53.0 million for the first six months of 2026. The company significantly strengthened its financial position by raising approximately $175.0 million in gross proceeds from a registered offering of common stock and pre-funded warrants in February 2026. As of June 30, 2026, cash, cash equivalents, and short-term investments totaled $236.9 million, which is expected to fund current planned operations into late 2027. The company also detailed ongoing investments in manufacturing infrastructure, including facility modifications and equipment purchases for its radiopharmaceutical product candidates.

Perspective Therapeutics reported a net loss of $26.8 million, or $0.22 per share, for the second quarter ended June 30, 2026. The company held approximately $237 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into late 2027. Key business highlights include advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, with site activation targeted around year-end 2026, and continued progress in other clinical programs. The company also announced manufacturing expansion plans and a new Chief Science Officer.

Perspective Therapeutics, Inc. reported a business update and Q2 2026 financial results, highlighting significant clinical progress and a strong financial position. The company is advancing its VMT-α-NET program toward a Phase 3 study in neuroendocrine tumors, with site activation targeted around year-end 2026. As of June 30, 2026, the company held approximately $237 million in cash, cash equivalents, and short-term investments, providing a cash runway into late 2027. For the second quarter, the net loss was $26.8 million, or $0.22 per share, as R&D expenses increased to $21.5 million.

Perspective Therapeutics, Inc. filed an updated corporate presentation highlighting its next-generation radiopharmaceutical pipeline. The presentation detailed progress in its diverse 212Pb-based oncology portfolio, including ongoing Phase 1/2a trials for VMT-α-NET in neuroendocrine tumors, VMT01 in melanoma, and PSV359 for solid tumors. The company reported promising preliminary anti-tumor activity and a favorable safety profile for VMT-α-NET, supporting potential registration studies, and initial anti-tumor activity for VMT01.

Perspective Therapeutics, Inc. announced that it will report its second quarter 2026 financial results and provide a business update on Monday, August 10, 2026. The announcement will be made after the market closes, with the press release available on the company's website.

Perspective Therapeutics announced that updated data for its [212Pb]VMT-α-NET program has been accepted for presentation at the European Society of Medical Oncology (ESMO) Congress 2026. The presentation, titled "Cohort level safety and efficacy results for [212Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)-expressing neuroendocrine tumors (NETs): Cohorts 1–3," will be a Rapid Oral presentation by Dr. Thorvardur Halfdanarson on October 23, 2026. This follows interim clinical data presented at the ASCO Annual Meeting in May 2026, highlighting ongoing progress in the company's radiopharmaceutical development.

Perspective Therapeutics, Inc. announced the appointment of Paul Lyne, Ph.D., as its new Chief Science Officer. Concurrently, co-founder and long-time CSO, Michael K. Schultz, Ph.D., has transitioned to the role of Senior Scientific Advisor & Co-Founder as part of a planned retirement. The company expects Dr. Lyne's extensive experience in oncology research and drug development to accelerate its scientific strategy and pipeline advancement, while Dr. Schultz's continued advisory role will ensure ongoing scientific guidance.

Perspective Therapeutics, Inc. updated its corporate presentation, detailing its strategy to redefine oncology treatment with next-generation radiopharmaceuticals. The presentation highlighted the advancement of its diverse 212Pb-based oncology portfolio, including positive Phase 1/2a data for VMT-α-NET in neuroendocrine tumors and initial anti-tumor activity for VMT01 in melanoma. The company also emphasized its integrated isotope production for direct-to-hospital delivery and a strong intellectual property portfolio.

Perspective Therapeutics announced that the first meningioma patient has been dosed with [212Pb]VMT-α-NET in its ongoing Phase 1/2a study. This new cohort, named LEMONαDE, aims to assess the safety, dosimetry, and preliminary anti-tumor activity of the lead-based alpha-particle therapy for meningioma, reflecting the company's strategy to expand evaluation beyond neuroendocrine tumors. Meningiomas are the most common primary brain tumors, often presenting limited treatment options for recurrent or unresectable cases, making them an attractive target due to consistent SSTR2 expression.